Changing the destination market after the URS is approved sends signed documents back into review.
The destination market is one of five questions we want answered before anyone prices a facility.
Between EU, WHO and US markets the building usually stays the same; what changes is the evidence it has to produce. Move a project from WHO-GMP to EU-GMP halfway through design and these come back: the URS, with its guideline references and acceptance criteria; the validation master plan; the DQ report written against the old URS; any IQ and OQ protocols already drafted; and, for a sterile product, the Contamination Control Strategy that Annex 1 expects. Each one means another round of review and signatures.
The other four questions on a scoping call:
- The process: dosage form, batch size, potency, open or closed handling.
- The grades and room list: how many rooms at Grade B, C and D, and what the pressure cascade protects.
- What already exists: a building, a utility plant, drawings, an old validation file. A utility plant that can be reused takes a package off the scope; one that turns out not to be reusable puts it back late.
- Which division you need first. Most clients start with one of our four, and none has to use all four.
Floor area comes after these. We fix the market in the design basis on day one, so the question is closed before the first document is signed.
Talk to an engineer: contact@humiley.com or +84 28 7777 6668 (Viet Nam office).
Industries




